Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Celestia Higano, MD
Seattle Cancer Care Alliance, US
Study Chair - Johann de Bono, Professor
Institute of Cancer Research, UK
Study Chair - Kim Chi, MD
Vancouver Prostate Centre, BC Cancer Agency, Canada
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
140 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Teva Investigational Site 862
Bonheiden, Belgium
- Teva Investigational Site 860
Brussels, Belgium
- Teva Investigational Site 864
Edegem, Belgium
- Teva Investigational Site 863
Ghent, Belgium
- Teva Investigational Site 002
Calgary, Alberta, Canada
- Teva Investigational Site 023
Edmonton, Alberta, Canada
- Teva Investigational Site 118
Abbotsford British Columbia, British Columbia, Canada
- Teva Investigational Site 007
Surrey, British Columbia, Canada
- Teva Investigational Site 001
Vancouver, British Columbia, Canada
- Teva Investigational Site 085
Victoria, British Columbia, Canada
- Teva Investigational Site 024
Winnipeg, Manitoba, Canada
- Teva Investigational Site 028
Halifax, Nova Scotia, Canada
- Teva Investigational Site 025
Hamilton, Ontario, Canada
- Teva Investigational Site 108
Kingston, Ontario, Canada
- Teva Investigational Site 091
Oshawa, Ontario, Canada
- Teva Investigational Site 003
Ottawa, Ontario, Canada
- Teva Investigational Site 004
Toronto, Ontario, Canada
- Teva Investigational Site 087
Toronto, Ontario, Canada
- Teva Investigational Site 026
Montreal, Quebec, Canada
- Teva Investigational Site 027
Montreal, Quebec, Canada
- Teva Investigational Site 551
Angers, France
- Teva Investigational Site 552
Avignon, France
- Teva Investigational Site 553
Grenoble, France
- Teva Investigational Site 555
La Roche-sur-Yon, France
- Teva Investigational Site 557
Marseille, France
- Teva Investigational Site 558
Nice, France
- Teva Investigational Site 559
Paris, France
- Teva Investigational Site 560
Paris, France
- Teva Investigational Site 566
Saint-Brieuc, France
- Teva Investigational Site 561
Saint-Herblain, France
- Teva Investigational Site 562
Saint-Priest-en-Jarez, France
- Teva Investigational Site 563
Toulouse, France
- Teva Investigational Site 564
Vandœuvre-lès-Nancy, France
- Teva Investigational Site 550
Villejuif, France
- Teva Investigational Site 607
Aachen, Germany
- Teva Investigational Site 609
Berlin, Germany
- Teva Investigational Site 613
Berlin, Germany
- Teva Investigational Site 604
Darmstadt, Germany
- Teva Investigational Site 612
Dresden, Germany
- Teva Investigational Site 618
Greifswald, Germany
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2010
- Primary completion
- 28 Feb 2014
- Completion
- 30 Jun 2014
- Last update posted
- 14 Oct 2016
- Registered enrollment
- 1,022
- Registry id
- NCT01188187
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.